vs
Side-by-side financial comparison of BingEx Ltd (FLX) and Vericel Corp (VCEL). Click either name above to swap in a different company.
BingEx Ltd is the larger business by last-quarter revenue ($143.2M vs $92.9M, roughly 1.5× Vericel Corp). Vericel Corp runs the higher net margin — 25.0% vs 2.2%, a 22.8% gap on every dollar of revenue.
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.
FLX vs VCEL — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $143.2M | $92.9M |
| Net Profit | $3.2M | $23.2M |
| Gross Margin | 10.8% | 78.7% |
| Operating Margin | — | 24.1% |
| Net Margin | 2.2% | 25.0% |
| Revenue YoY | — | 23.3% |
| Net Profit YoY | — | 17.3% |
| EPS (diluted) | — | $0.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $143.2M | — | ||
| Q4 25 | — | $92.9M | ||
| Q3 25 | $141.2M | $67.5M | ||
| Q2 25 | $143.0M | $63.2M | ||
| Q1 25 | $141.0M | $52.6M | ||
| Q4 24 | — | $75.4M | ||
| Q3 24 | $164.6M | $57.9M | ||
| Q2 24 | — | $52.7M |
| Q1 26 | $3.2M | — | ||
| Q4 25 | — | $23.2M | ||
| Q3 25 | $6.1M | $5.1M | ||
| Q2 25 | $7.5M | $-553.0K | ||
| Q1 25 | $27.6M | $-11.2M | ||
| Q4 24 | — | $19.8M | ||
| Q3 24 | $3.4M | $-901.0K | ||
| Q2 24 | — | $-4.7M |
| Q1 26 | 10.8% | — | ||
| Q4 25 | — | 78.7% | ||
| Q3 25 | 11.1% | 73.5% | ||
| Q2 25 | 12.0% | 73.7% | ||
| Q1 25 | 10.0% | 69.0% | ||
| Q4 24 | — | 77.6% | ||
| Q3 24 | 11.3% | 71.9% | ||
| Q2 24 | — | 69.5% |
| Q1 26 | — | — | ||
| Q4 25 | — | 24.1% | ||
| Q3 25 | 1.4% | 5.1% | ||
| Q2 25 | 1.9% | -3.2% | ||
| Q1 25 | — | -24.3% | ||
| Q4 24 | — | 24.5% | ||
| Q3 24 | 4.0% | -4.3% | ||
| Q2 24 | — | -11.5% |
| Q1 26 | 2.2% | — | ||
| Q4 25 | — | 25.0% | ||
| Q3 25 | 4.4% | 7.5% | ||
| Q2 25 | 5.2% | -0.9% | ||
| Q1 25 | 19.6% | -21.4% | ||
| Q4 24 | — | 26.3% | ||
| Q3 24 | 2.1% | -1.6% | ||
| Q2 24 | — | -8.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | $0.46 | ||
| Q3 25 | — | $0.10 | ||
| Q2 25 | — | $-0.01 | ||
| Q1 25 | — | $-0.23 | ||
| Q4 24 | — | $0.40 | ||
| Q3 24 | — | $-0.02 | ||
| Q2 24 | — | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $561.1M | $137.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $354.6M |
| Total Assets | $1.3B | $488.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $561.1M | — | ||
| Q4 25 | — | $137.5M | ||
| Q3 25 | $628.6M | $135.4M | ||
| Q2 25 | $499.4M | $116.9M | ||
| Q1 25 | $592.4M | $112.9M | ||
| Q4 24 | — | $116.2M | ||
| Q3 24 | $517.4M | $101.7M | ||
| Q2 24 | — | $102.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | $354.6M | ||
| Q3 25 | — | $321.9M | ||
| Q2 25 | — | $306.8M | ||
| Q1 25 | — | $295.5M | ||
| Q4 24 | — | $292.0M | ||
| Q3 24 | — | $257.5M | ||
| Q2 24 | — | $243.0M |
| Q1 26 | $1.3B | — | ||
| Q4 25 | — | $488.0M | ||
| Q3 25 | $1.3B | $453.3M | ||
| Q2 25 | $1.2B | $435.6M | ||
| Q1 25 | $1.2B | $424.6M | ||
| Q4 24 | — | $432.7M | ||
| Q3 24 | $926.8M | $390.4M | ||
| Q2 24 | — | $376.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $15.0M |
| Free Cash FlowOCF − Capex | — | $12.8M |
| FCF MarginFCF / Revenue | — | 13.8% |
| Capex IntensityCapex / Revenue | — | 2.4% |
| Cash ConversionOCF / Net Profit | — | 0.65× |
| TTM Free Cash FlowTrailing 4 quarters | — | $24.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $15.0M | ||
| Q3 25 | — | $22.1M | ||
| Q2 25 | — | $8.2M | ||
| Q1 25 | — | $6.6M | ||
| Q4 24 | — | $22.2M | ||
| Q3 24 | — | $10.2M | ||
| Q2 24 | — | $18.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | $12.8M | ||
| Q3 25 | — | $19.5M | ||
| Q2 25 | — | $81.0K | ||
| Q1 25 | — | $-7.6M | ||
| Q4 24 | — | $8.5M | ||
| Q3 24 | — | $-9.2M | ||
| Q2 24 | — | $1.8M |
| Q1 26 | — | — | ||
| Q4 25 | — | 13.8% | ||
| Q3 25 | — | 28.8% | ||
| Q2 25 | — | 0.1% | ||
| Q1 25 | — | -14.5% | ||
| Q4 24 | — | 11.2% | ||
| Q3 24 | — | -15.9% | ||
| Q2 24 | — | 3.4% |
| Q1 26 | — | — | ||
| Q4 25 | — | 2.4% | ||
| Q3 25 | — | 3.9% | ||
| Q2 25 | — | 12.9% | ||
| Q1 25 | — | 27.0% | ||
| Q4 24 | — | 18.3% | ||
| Q3 24 | — | 33.5% | ||
| Q2 24 | — | 31.8% |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.65× | ||
| Q3 25 | — | 4.35× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.12× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FLX
Segment breakdown not available.
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
